Subcutaneous · GLP-1 / glucagon dual
Cotadutide
24 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
24
Active
0
Recruiting
0
Completed
22
Sites
341
Countries
31
Endpoints
450
Composite endpoints
15
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Phase 1
12
Phase 1/2
1
Phase 2
11
Trials by status
Completed
22
Terminated
2
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
264
Glycemic / diabetes
87
Weight & body composition
50
Cardiometabolic biomarkers
28
MASH / liver
13
Renal / kidney
4
Other clinical outcomes
2
Other (unclassified)
2
Most-measured metrics
Top 20 metrics across this asset's endpoints
Treatment-emergent AEs (any)Safety/PK
60
AUC₀–∞Safety/PK
35
Immunogenicity (ADA)Safety/PK
30
CmaxSafety/PK
21
Body weight, % changeWeight
19
TmaxSafety/PK
18
HbA1c, changeGlycemic
13
Body weight, absolute change (kg)Weight
13
Fasting glucose, changeGlycemic
12
Half-lifeSafety/PK
11
Postprandial glucoseGlycemic
11
Plasma concentration (steady state)Safety/PK
11
Heart rate, changeBiomarker
11
CGM time-above-rangeGlycemic
10
HbA1c, % changeGlycemic
5
≥5% weight-loss respondersWeight
4
CGM time-below-rangeGlycemic
4
CGM time-in-rangeGlycemic
4
Systolic BP, changeBiomarker
4
uACR, % changeRenal
4
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
24 of 24